Mesa Laboratories (NASDAQ:MLAB) CFO John Sakys Sells 1,223 Shares

Posted by George Bondi on Jun 18th, 2026

Mesa Laboratories, Inc. (NASDAQ:MLAB – Get Free Report) CFO John Sakys sold 1,223 shares of the firm’s stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $101.27, for a total value of $123,853.21. Following the completion of the sale, the chief financial officer owned 16,538 shares in the company, valued at $1,674,803.26. The trade was a 6.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Mesa Laboratories Price Performance

Shares of MLAB opened at $94.95 on Thursday. The stock’s fifty day moving average is $101.90 and its 200-day moving average is $90.64. The firm has a market capitalization of $524.12 million, a price-to-earnings ratio of 79.13 and a beta of 0.94. Mesa Laboratories, Inc. has a one year low of $55.45 and a one year high of $113.99. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.29 and a current ratio of 1.72.

Mesa Laboratories (NASDAQ:MLAB – Get Free Report) last announced its quarterly earnings data on Wednesday, May 27th. The medical instruments supplier reported $1.53 EPS for the quarter, missing analysts’ consensus estimates of $1.78 by ($0.25). The business had revenue of $63.72 million for the quarter, compared to analyst estimates of $65.21 million. Mesa Laboratories had a return on equity of 20.96% and a net margin of 2.69%.During the same quarter in the previous year, the business posted ($1.31) earnings per share.

Mesa Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, June 15th. Stockholders of record on Friday, May 29th were given a dividend of $0.16 per share. The ex-dividend date was Friday, May 29th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.7%. Mesa Laboratories’s payout ratio is currently 53.33%.

Institutional Investors Weigh In On Mesa Laboratories

Hedge funds have recently added to or reduced their stakes in the business. Royal Bank of Canada increased its holdings in Mesa Laboratories by 1.2% during the 1st quarter. Royal Bank of Canada now owns 30,772 shares of the medical instruments supplier’s stock worth $3,652,000 after purchasing an additional 353 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new position in shares of Mesa Laboratories in the first quarter worth approximately $335,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Mesa Laboratories by 4.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 3,068 shares of the medical instruments supplier’s stock valued at $364,000 after purchasing an additional 143 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Mesa Laboratories by 3.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 19,977 shares of the medical instruments supplier’s stock valued at $2,370,000 after acquiring an additional 685 shares during the last quarter. Finally, American Century Companies Inc. increased its holdings in Mesa Laboratories by 1.5% during the 2nd quarter. American Century Companies Inc. now owns 13,431 shares of the medical instruments supplier’s stock valued at $1,265,000 after purchasing an additional 194 shares during the period. 90.60% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings downgraded Mesa Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a report on Wednesday, June 3rd. Two analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Reduce” and a consensus target price of $94.00.

Get Our Latest Research Report on Mesa Laboratories

About Mesa Laboratories

(Get Free Report)

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.